Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 and midazolam drug-drug interaction study in advanced non-small cell lung cancer
NL-OMON49519Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mobocertinib and midazolam in non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoints: Geometric mean ratio of midazolam Cmax after oral administration with and without TAK-788, Geometric mean ratio of midazolam AUC after oral administration with and without TAK-788 and 2 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
mobocertinibmidazolam
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49519.